Recent Updates
Recently added Catalysts

Upcoming Catalyst

Drug Pipeline Intelligence

Clinical Trial Results

Inside Trades

Options Data

News Section

Hedge Funds

Ownership Trends

Competitive Position

GlycoMimetics, Inc.

$15.7

-1.02 (-6.1%)

C 40Pipeline Score Fair Value Pharma · Clinical
Market Cap
10.13 M
EPS
-0.46
P/E Ratio
-
Value Trade
171.00 K
0 %
Week
0 %
1 Month
0 %
3 Month
0 %
6 Month
0 %
5 Year
-98.49 %
All Time
Cash Data

  • Cash Position

    12.35 K

  • Monthly Burn

    12.35 K

  • Runway

    12,345 mo

Overview
Volume
10.69 K
52 Week Range
null-null
% held by Insiders
21.43 %
% held by Institutions
78.98 %
Enterprise Value
4.52 M
Total Shares
64.53 M
Short %
15.04 %
Float Shares
56.12 M
Company Description

locked

Upcoming Catalyst
Catalyst Drug/Treatment Stage Probability of Approval Description Drug Type Therapeutic Area Source
Preclinical data readout example
CR-001 tetravalent PD-1 x VEGF bispecific antibody
Pre-clinical
—
Antibody-Drug Conjugates (ADCs)
Oncology
CR-001 tetravalent PD-1 x VEGF bispecific antibody
Pre-clinical
—
Antibody-Drug Conjugates (ADCs)
Oncology
CR-001 tetravalent PD-1 x VEGF bispecific antibody
Pre-clinical
—
Antibody-Drug Conjugates (ADCs)
Oncology
Unlock Upcoming Catalyst data
Drug Pipeline Intelligence
C40
Pipeline Score
$8M
Pipeline Value
Fair Value
Valuation Signal
5
Drugs Scored
0.8x
rNPV / MCap
Top 58%
Micro Cap
(rank 381 of 905)
Percentile Rank
GlycoMimetics, Inc. carries a moderate pipeline score (40/100), with $2.4B risk-adjusted pipeline value, led by Rivipansel in Anemia, Sickle Cell (Phase 3), across $76B in total addressable markets.
Showing 1 of 1 assets
DrugIndicationPhaseNCT IDPTRSrNPVStatusEnrollmentVelocityDesignCompletionML SignalLast Change
Rivipansel
Small molecule		Anemia, Sickle CellPhase 3NCT0218700368% $964M COMPLETED 345 - -Jun 27, 2019 -Mar 11, 2025
Unlock Drug Pipeline Intelligence
Clinical Trial Results
Drug Name Indications Phase Date Trial Results Summary Title Source
Example Drug
Example indication for clinical evaluation
Phase 3
2025-12-01
Example Drug
Example indication for clinical evaluation
Phase 3
2025-12-01
Example Drug
Example indication for clinical evaluation
Phase 3
2025-12-01
Unlock Clinical Trial Results data
Inside Trades
TREND
CORPORATE INSIDERS BOUGHT SHARES WORTH 1.8M IN THE LAST 3 MONTHS
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Unlock Inside Trades data
Show Data
Hedge Funds
TREND
HEDGE FUNDS INCREASED HOLDINGS BY 200.0K SHARES IN THE LAST QUARTER
Shares Held
2040.00B1530.00B1020.00B510.00B0
Q3
2024
Q4
2024
Q1
2025
Q2
2025
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Fund Count
60%
Share Volume
25%
Conviction
15%
Hedge Funds invested in GLYC
HedgeFund Name
( 3 )
% of Portfolio Current MV
-
Shares Owned
-
Activity
Avg Price $0

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K
Unlock Hedge Funds table data
GlycoMimetics, Inc. (GLYC) Analyst Ratings & Price Targets
Symbol
Firm
Rating
Action
Price Target
Upside
date
GLYC
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
GLYC
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
GLYC
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
Unlock Biotech Analyst Ratings data
GLYC Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
Unlock Price Target Trend
GLYC Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
ExpirationVolumeOpen InterestImplied Volatility CallsImplied Volatility Puts
CallsPutsPut-Call RatioCallsPutsPut-Call RatioIVOiWaIvVWaIvIVOiWaIvVWaIv
Unlock Option Chain Statistics data
Option Chain
CallsStrikePuts
Last PriceVolumeOpen InterestLast PriceVolumeOpen Interest
No data available
Unlock Option Chain data
Unlock Options Chart data
Open interest
0 600K 1.2M 1.8M Avg OI 1.00 M Open Interest
0 1 2 3 1.1 Put-Call Ratio
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
0 450K 900K 1.4M Avg OV 750.00 K Option Volume
0 1 2 3 0.95 Put-Call Ratio
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
Competitive Position
How GLYC ranks across every disease it competes in
Competitive Position is a premium feature
See how GLYC ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial